tiprankstipranks
Trending News
More News >

Petros Pharmaceuticals Faces Nasdaq Delisting Notice

Story Highlights
Petros Pharmaceuticals Faces Nasdaq Delisting Notice

Confident Investing Starts Here:

The latest announcement is out from Petros Pharmaceuticals ( (PTPI) ).

On May 20, 2025, Petros Pharmaceuticals received a delisting notice from the Nasdaq Hearings Panel due to non-compliance with several Nasdaq listing rules, including minimum stockholders’ equity and bid price requirements. Consequently, the company’s stock will be suspended from Nasdaq trading on May 22, 2025, and is expected to trade on the OTC Markets under the symbol ‘PTPI’. The company plans to appeal the delisting decision, although there is no guarantee of a favorable outcome.

The most recent analyst rating on (PTPI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Petros Pharmaceuticals stock, see the PTPI Stock Forecast page.

More about Petros Pharmaceuticals

Petros Pharmaceuticals, Inc. operates in the pharmaceutical industry, focusing on the development and commercialization of therapeutics for men’s health issues.

Average Trading Volume: 7,791,091

Technical Sentiment Signal: Sell

Current Market Cap: $4.12M

For a thorough assessment of PTPI stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App